Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT01204749




Registration number
NCT01204749
Ethics application status
Date submitted
26/08/2010
Date registered
17/09/2010
Date last updated
15/12/2016

Titles & IDs
Public title
TRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube Cancer
Scientific title
A Phase 3, Randomized, Double-Blind Trial of Weekly Paclitaxel Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers
Secondary ID [1] 0 0
20090508
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Fallopian Tube Cancer 0 0
Ovarian Cancer 0 0
Primary Peritoneal Cancer 0 0
Condition category
Condition code
Cancer 0 0 0 0
Ovarian and primary peritoneal
Cancer 0 0 0 0
Womb (Uterine or endometrial cancer)
Cancer 0 0 0 0
Stomach

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - AMG 386
Treatment: Drugs - AMG 386 Placebo
Treatment: Drugs - Paclitaxel
Treatment: Drugs - Paclitaxel

Experimental: AMG 386 - Arm A: Paclitaxel 80mg/m2 IV QW and Blinded AMG 386 15mg/kg IV QW

Placebo comparator: AMG 386 Placebo - Arm B: Paclitaxel 80mg/m2 IV QW and Blinded AMG 386 Placebo IV QW


Treatment: Drugs: AMG 386
Weekly Intravenous (IV) AMG 386 15 mg/kg

Treatment: Drugs: AMG 386 Placebo
Weekly Intravenous (IV) placebo 15 mg/kg

Treatment: Drugs: Paclitaxel
Paclitaxel 80 mg/m2 intravenous (IV) weekly (3 on/1 off)

Treatment: Drugs: Paclitaxel
Paclitaxel 80 mg/m2 intravenous (IV) weekly (3 on/1 off)
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Progression-Free Survival
Timepoint [1] 0 0
8 Months on average
Secondary outcome [1] 0 0
Overall survival
Timepoint [1] 0 0
20 months on average
Secondary outcome [2] 0 0
Objective Response Rate
Timepoint [2] 0 0
From Baseline (if subject has Measurable Disease) until objective response (radiologic)
Secondary outcome [3] 0 0
Duration of response
Timepoint [3] 0 0
From Baseline until progression
Secondary outcome [4] 0 0
CA-125 response rate per Gynecologic Cancer Intergroup (GCIG) and change in CA-125
Timepoint [4] 0 0
From Baseline until CA-125 response
Secondary outcome [5] 0 0
Incidence of adverse events and significant laboratory abnormalities
Timepoint [5] 0 0
8 Months on average
Secondary outcome [6] 0 0
Pharmacokinetics of AMG 386 (Cmax and Cmin)
Timepoint [6] 0 0
Week 1 until week 9 of treatment
Secondary outcome [7] 0 0
Incidence of the occurrence of anti-AMG 386 antibody formation
Timepoint [7] 0 0
Week 1 until maximum of 1-year following last dose of study drug
Secondary outcome [8] 0 0
Patient reported Health Related Quality of Life (HRQOL) and ovarian cancer related symptoms using Functional Assessment of Cancer Therapy - Ovary questionnaire (FACT-O)
Timepoint [8] 0 0
From week 1 until 30-days following last study drug administration
Secondary outcome [9] 0 0
Overall health status using EuroQOL(EQ-5D)
Timepoint [9] 0 0
From week 1 until 30-days following last study drug administration

Eligibility
Key inclusion criteria
* Female 18 years of age or older at the time the written informed consent is obtained
* Gynecologic Oncology Group (GOG) Performance Status of 0 or 1
* Life expectancy >= 3 months (per investigator opinion)
* Histologically or cytologically documented invasive epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer (Subjects with pseudomyxoma , mesothelioma, unknown primary tumor, sarcoma, or neuroendocrine histology, with borderline ovarian cancer, ie, subjects with low malignant potential tumors, and with clear cell or mucinous histology are excluded)
* Subjects must have undergone surgery for ovarian cancer, primary peritoneal cancer, or fallopian tube cancer including at least a unilateral oophorectomy
* Radiologically evaluable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 with modifications
* Subjects must have had one prior platinum-based chemotherapeutic regimen for management of primary disease containing carboplatin, cisplatin, or another organoplatinum compound. This initial treatment may have included intraperitoneal therapy, high-dose therapy, consolidation therapy, bevacizumab or extended therapy administered after surgical or non-surgical assessment.
* Adequate organ and hematological function
* Generally well controlled blood pressure with systolic blood pressure <= 140 mmHg and diastolic blood pressure <= 90 mmHg prior to randomization. The use of anti-hypertensive medications to control hypertension is permitted
* Radiographically documented disease progression either on or following the last dose of prior chemotherapy regimen for epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer
Minimum age
18 Years
Maximum age
No limit
Sex
Females
Can healthy volunteers participate?
No
Key exclusion criteria
* Subjects who have received more than 3 previous regimens of anti-cancer therapy for epithelial ovarian, primary peritoneal or fallopian tube cancers
* Subjects who have received paclitaxel as consolidation therapy, maintenance, or monotherapy are excluded
* Subjects with primary platinum-refractory disease
* Subjects with platinum-free interval (PFI) > 12 months from their last platinum based therapy
* Radiotherapy <= 14 days prior to randomization. Subjects must have recovered from all radiotherapy-related toxicities
* Previous abdominal or pelvic radiotherapy
* History of arterial or venous thromboembolism within 12 months prior to randomization
* History of clinically significant bleeding within 6 months prior to randomization
* History of central nervous system metastasis
* Has not yet completed a 21 day washout period prior to randomization for any previous anti cancer systemic therapies (30 days for prior bevacizumab)
* Enrolled in or has not yet completed at least 30 days (prior to randomization) since ending other investigational device or drug, or currently receiving other investigational treatments
* Unresolved toxicities from prior systemic therapy that are Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 >= Grade 2 in severity except alopecia
* Known active or ongoing infection (except uncomplicated urinary tract infection [UTI]) within 14 days prior to randomization
* Currently or previously treated with AMG 386, or other molecules that inhibit the angiopoietins or Tie2 receptor
* Treatment within 30 days prior to randomization with strong immune modulators including but not limited to systemic cyclosporine, tacrolimus, sirolimus, mycophenolate mofetil, methotrexate, azathioprine, rapamycin, thalidomide, and lenalidomide
* Clinically significant cardiovascular disease within 12 months prior to randomization
* Major surgery within 28 days prior to randomization or still recovering from prior surgery
* Minor surgical procedures, except placement of tunneled central venous access device within 3 days prior to randomization. Diagnostic laparoscopy is regarded as a minor surgical procedure.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/11/2010
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/12/2016
Sample size
Target
Accrual to date
Final
919
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC
Recruitment hospital [1] 0 0
Research Site - New Lambton Heights
Recruitment hospital [2] 0 0
Research Site - Greenslopes
Recruitment hospital [3] 0 0
Research Site - Bendigo
Recruitment hospital [4] 0 0
Research Site - Bentleigh East
Recruitment hospital [5] 0 0
Research Site - Footscray
Recruitment hospital [6] 0 0
Research Site - Malvern
Recruitment hospital [7] 0 0
Research Site - Parkville
Recruitment postcode(s) [1] 0 0
2305 - New Lambton Heights
Recruitment postcode(s) [2] 0 0
4120 - Greenslopes
Recruitment postcode(s) [3] 0 0
3550 - Bendigo
Recruitment postcode(s) [4] 0 0
3165 - Bentleigh East
Recruitment postcode(s) [5] 0 0
3011 - Footscray
Recruitment postcode(s) [6] 0 0
3144 - Malvern
Recruitment postcode(s) [7] 0 0
3052 - Parkville
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Colorado
Country [4] 0 0
United States of America
State/province [4] 0 0
Connecticut
Country [5] 0 0
United States of America
State/province [5] 0 0
Florida
Country [6] 0 0
United States of America
State/province [6] 0 0
Hawaii
Country [7] 0 0
United States of America
State/province [7] 0 0
Idaho
Country [8] 0 0
United States of America
State/province [8] 0 0
Illinois
Country [9] 0 0
United States of America
State/province [9] 0 0
Louisiana
Country [10] 0 0
United States of America
State/province [10] 0 0
Maryland
Country [11] 0 0
United States of America
State/province [11] 0 0
Massachusetts
Country [12] 0 0
United States of America
State/province [12] 0 0
New Hampshire
Country [13] 0 0
United States of America
State/province [13] 0 0
New Jersey
Country [14] 0 0
United States of America
State/province [14] 0 0
New York
Country [15] 0 0
United States of America
State/province [15] 0 0
North Carolina
Country [16] 0 0
United States of America
State/province [16] 0 0
Pennsylvania
Country [17] 0 0
United States of America
State/province [17] 0 0
Tennessee
Country [18] 0 0
United States of America
State/province [18] 0 0
Texas
Country [19] 0 0
United States of America
State/province [19] 0 0
Utah
Country [20] 0 0
United States of America
State/province [20] 0 0
Washington
Country [21] 0 0
United States of America
State/province [21] 0 0
Wisconsin
Country [22] 0 0
Belgium
State/province [22] 0 0
Edegem
Country [23] 0 0
Belgium
State/province [23] 0 0
Leuven
Country [24] 0 0
Belgium
State/province [24] 0 0
Namur
Country [25] 0 0
Brazil
State/province [25] 0 0
Rio Grande do Sul
Country [26] 0 0
Brazil
State/province [26] 0 0
Santa Catarina
Country [27] 0 0
Brazil
State/province [27] 0 0
São Paulo
Country [28] 0 0
Brazil
State/province [28] 0 0
Rio de Janeiro
Country [29] 0 0
Bulgaria
State/province [29] 0 0
Gabrovo
Country [30] 0 0
Bulgaria
State/province [30] 0 0
Plovdiv
Country [31] 0 0
Bulgaria
State/province [31] 0 0
Sofia
Country [32] 0 0
Bulgaria
State/province [32] 0 0
Stara Zagora
Country [33] 0 0
Bulgaria
State/province [33] 0 0
Varna
Country [34] 0 0
Canada
State/province [34] 0 0
Alberta
Country [35] 0 0
Canada
State/province [35] 0 0
British Columbia
Country [36] 0 0
Canada
State/province [36] 0 0
Ontario
Country [37] 0 0
Canada
State/province [37] 0 0
Quebec
Country [38] 0 0
Chile
State/province [38] 0 0
CautÃ-n
Country [39] 0 0
Chile
State/province [39] 0 0
ValparaÃ-so
Country [40] 0 0
Croatia
State/province [40] 0 0
Zagreb
Country [41] 0 0
Czech Republic
State/province [41] 0 0
Brno
Country [42] 0 0
Czech Republic
State/province [42] 0 0
Praha 2
Country [43] 0 0
Czech Republic
State/province [43] 0 0
Praha 5
Country [44] 0 0
Estonia
State/province [44] 0 0
Tallinn
Country [45] 0 0
Estonia
State/province [45] 0 0
Tartu
Country [46] 0 0
France
State/province [46] 0 0
Amiens
Country [47] 0 0
France
State/province [47] 0 0
Angers
Country [48] 0 0
France
State/province [48] 0 0
Avignon Cedex 2
Country [49] 0 0
France
State/province [49] 0 0
Bayonne
Country [50] 0 0
France
State/province [50] 0 0
Besancon Cedex
Country [51] 0 0
France
State/province [51] 0 0
Bordeaux Cedex
Country [52] 0 0
France
State/province [52] 0 0
Brest Cedex 2
Country [53] 0 0
France
State/province [53] 0 0
Dijon
Country [54] 0 0
France
State/province [54] 0 0
Le Mans
Country [55] 0 0
France
State/province [55] 0 0
Lille Cedex
Country [56] 0 0
France
State/province [56] 0 0
Lyon
Country [57] 0 0
France
State/province [57] 0 0
Marseille cedex 05
Country [58] 0 0
France
State/province [58] 0 0
Marseille Cedex 09
Country [59] 0 0
France
State/province [59] 0 0
Marseille
Country [60] 0 0
France
State/province [60] 0 0
Montpellier Cedex 5
Country [61] 0 0
France
State/province [61] 0 0
Nancy
Country [62] 0 0
France
State/province [62] 0 0
Nantes Cedex 2
Country [63] 0 0
France
State/province [63] 0 0
Nice cedex 2
Country [64] 0 0
France
State/province [64] 0 0
Orléans cedex 2
Country [65] 0 0
France
State/province [65] 0 0
Paris cedex 15
Country [66] 0 0
France
State/province [66] 0 0
Périgueux cedex
Country [67] 0 0
France
State/province [67] 0 0
Reims Cedex
Country [68] 0 0
France
State/province [68] 0 0
Saint Grégoire cedex
Country [69] 0 0
France
State/province [69] 0 0
Saint Herblain
Country [70] 0 0
France
State/province [70] 0 0
Strasbourg
Country [71] 0 0
France
State/province [71] 0 0
Villejuif cedex
Country [72] 0 0
Greece
State/province [72] 0 0
Athens
Country [73] 0 0
Greece
State/province [73] 0 0
Heraklion
Country [74] 0 0
Greece
State/province [74] 0 0
Larissa
Country [75] 0 0
Greece
State/province [75] 0 0
Patra
Country [76] 0 0
Greece
State/province [76] 0 0
Thessaloniki
Country [77] 0 0
Hong Kong
State/province [77] 0 0
Hong Kong
Country [78] 0 0
India
State/province [78] 0 0
Andhra Pradesh
Country [79] 0 0
India
State/province [79] 0 0
Maharashtra
Country [80] 0 0
Israel
State/province [80] 0 0
Haifa
Country [81] 0 0
Israel
State/province [81] 0 0
Holon
Country [82] 0 0
Israel
State/province [82] 0 0
Kefar Sava
Country [83] 0 0
Israel
State/province [83] 0 0
Tel Hashomer
Country [84] 0 0
Israel
State/province [84] 0 0
Tel-Aviv
Country [85] 0 0
Italy
State/province [85] 0 0
Benevento
Country [86] 0 0
Italy
State/province [86] 0 0
Catania
Country [87] 0 0
Italy
State/province [87] 0 0
Cosenza (CS)
Country [88] 0 0
Italy
State/province [88] 0 0
Genova
Country [89] 0 0
Italy
State/province [89] 0 0
Milano
Country [90] 0 0
Italy
State/province [90] 0 0
Napoli
Country [91] 0 0
Italy
State/province [91] 0 0
Padova
Country [92] 0 0
Italy
State/province [92] 0 0
Potenza
Country [93] 0 0
Italy
State/province [93] 0 0
Roma
Country [94] 0 0
Japan
State/province [94] 0 0
Aichi
Country [95] 0 0
Japan
State/province [95] 0 0
Fukuoka
Country [96] 0 0
Japan
State/province [96] 0 0
Hiroshima
Country [97] 0 0
Japan
State/province [97] 0 0
Hokkaido
Country [98] 0 0
Japan
State/province [98] 0 0
Ibaraki
Country [99] 0 0
Japan
State/province [99] 0 0
Iwate
Country [100] 0 0
Japan
State/province [100] 0 0
Niigata
Country [101] 0 0
Japan
State/province [101] 0 0
Osaka
Country [102] 0 0
Japan
State/province [102] 0 0
Saitama
Country [103] 0 0
Japan
State/province [103] 0 0
Shizuoka
Country [104] 0 0
Japan
State/province [104] 0 0
Tokyo
Country [105] 0 0
Japan
State/province [105] 0 0
Tottori
Country [106] 0 0
Japan
State/province [106] 0 0
Kurume-city
Country [107] 0 0
Korea, Republic of
State/province [107] 0 0
Goyang-si, Gyeonggi-do
Country [108] 0 0
Korea, Republic of
State/province [108] 0 0
Seoul
Country [109] 0 0
Latvia
State/province [109] 0 0
Daugavpils
Country [110] 0 0
Latvia
State/province [110] 0 0
Riga
Country [111] 0 0
Malaysia
State/province [111] 0 0
Johor
Country [112] 0 0
Malaysia
State/province [112] 0 0
Kelantan
Country [113] 0 0
Malaysia
State/province [113] 0 0
Wilayah Persekutuan
Country [114] 0 0
Mexico
State/province [114] 0 0
Distrito Federal
Country [115] 0 0
Mexico
State/province [115] 0 0
San Luis PotosÃ-
Country [116] 0 0
Peru
State/province [116] 0 0
Lima
Country [117] 0 0
Poland
State/province [117] 0 0
Bydgoszcz
Country [118] 0 0
Poland
State/province [118] 0 0
Gdansk
Country [119] 0 0
Poland
State/province [119] 0 0
Lodz
Country [120] 0 0
Poland
State/province [120] 0 0
Lublin
Country [121] 0 0
Poland
State/province [121] 0 0
Poznan
Country [122] 0 0
Poland
State/province [122] 0 0
Warszawa
Country [123] 0 0
Portugal
State/province [123] 0 0
Coimbra
Country [124] 0 0
Portugal
State/province [124] 0 0
Guimaraes
Country [125] 0 0
Portugal
State/province [125] 0 0
Lisboa
Country [126] 0 0
Portugal
State/province [126] 0 0
Porto
Country [127] 0 0
Portugal
State/province [127] 0 0
Santa Maria da Feira
Country [128] 0 0
Romania
State/province [128] 0 0
Bucharest
Country [129] 0 0
Romania
State/province [129] 0 0
Cluj Napoca
Country [130] 0 0
Romania
State/province [130] 0 0
Suceava
Country [131] 0 0
Romania
State/province [131] 0 0
Targu Mures
Country [132] 0 0
Russian Federation
State/province [132] 0 0
Ivanovo
Country [133] 0 0
Russian Federation
State/province [133] 0 0
Krasnodar
Country [134] 0 0
Russian Federation
State/province [134] 0 0
Moscow
Country [135] 0 0
Russian Federation
State/province [135] 0 0
Obninsk
Country [136] 0 0
Russian Federation
State/province [136] 0 0
Pyatigorsk
Country [137] 0 0
Russian Federation
State/province [137] 0 0
Saint Petersburg
Country [138] 0 0
Russian Federation
State/province [138] 0 0
Ufa
Country [139] 0 0
Russian Federation
State/province [139] 0 0
Voronezh
Country [140] 0 0
Slovenia
State/province [140] 0 0
Ljubljana
Country [141] 0 0
South Africa
State/province [141] 0 0
Gauteng
Country [142] 0 0
South Africa
State/province [142] 0 0
Western Cape
Country [143] 0 0
South Africa
State/province [143] 0 0
Observatory
Country [144] 0 0
South Africa
State/province [144] 0 0
Port Elizabeth
Country [145] 0 0
South Africa
State/province [145] 0 0
Pretoria
Country [146] 0 0
Spain
State/province [146] 0 0
AndalucÃ-a
Country [147] 0 0
Spain
State/province [147] 0 0
Baleares
Country [148] 0 0
Spain
State/province [148] 0 0
Castilla León
Country [149] 0 0
Spain
State/province [149] 0 0
Cataluña
Country [150] 0 0
Spain
State/province [150] 0 0
Comunidad Valenciana
Country [151] 0 0
Spain
State/province [151] 0 0
Galicia
Country [152] 0 0
Spain
State/province [152] 0 0
PaÃ-s Vasco
Country [153] 0 0
Spain
State/province [153] 0 0
Madrid
Country [154] 0 0
Sweden
State/province [154] 0 0
Umeå
Country [155] 0 0
Sweden
State/province [155] 0 0
Uppsala
Country [156] 0 0
Switzerland
State/province [156] 0 0
Baden
Country [157] 0 0
Switzerland
State/province [157] 0 0
Bellinzona
Country [158] 0 0
Switzerland
State/province [158] 0 0
Chur
Country [159] 0 0
Switzerland
State/province [159] 0 0
Geneva 14
Country [160] 0 0
Switzerland
State/province [160] 0 0
Zurich
Country [161] 0 0
United Kingdom
State/province [161] 0 0
London
Country [162] 0 0
United Kingdom
State/province [162] 0 0
Manchester
Country [163] 0 0
United Kingdom
State/province [163] 0 0
Northwood
Country [164] 0 0
United Kingdom
State/province [164] 0 0
Nottingham
Country [165] 0 0
United Kingdom
State/province [165] 0 0
Poole
Country [166] 0 0
United Kingdom
State/province [166] 0 0
Sutton

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Amgen
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to determine if treatment with paclitaxel plus AMG 386 is superior to paclitaxel plus placebo in women with recurrent partially platinum sensitive or resistant epithelial ovarian cancer, primary peritoneal cancer or fallopian tube cancer.

AMG 386 is a man-made medication that is designed to stop the development of blood vessels in cancer tissues. Cancer tissues rely on the development of new blood vessels, a process called angiogenesis, to obtain a supply of oxygen and nutrients to grow.
Trial website
https://clinicaltrials.gov/study/NCT01204749
Trial related presentations / publications
Monk BJ, Poveda A, Vergote I, Raspagliesi F, Fujiwara K, Bae DS, Oaknin A, Ray-Coquard I, Provencher DM, Karlan BY, Lhomme C, Richardson G, Rincon DG, Coleman RL, Herzog TJ, Marth C, Brize A, Fabbro M, Redondo A, Bamias A, Tassoudji M, Navale L, Warner DJ, Oza AM. Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 2014 Jul;15(8):799-808. doi: 10.1016/S1470-2045(14)70244-X. Epub 2014 Jun 17.
Monk BJ, Poveda A, Vergote I, Raspagliesi F, Fujiwara K, Bae DS, Oaknin A, Ray-Coquard I, Provencher DM, Karlan BY, Lhomme C, Richardson G, Rincon DG, Coleman RL, Marth C, Brize A, Fabbro M, Redondo A, Bamias A, Ma H, Vogl FD, Bach BA, Oza AM. Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): Long-term survival, impact of ascites, and progression-free survival-2. Gynecol Oncol. 2016 Oct;143(1):27-34. doi: 10.1016/j.ygyno.2016.07.112. Epub 2016 Aug 18.
Fujiwara K, Monk BJ, Lhomme C, Coleman RL, Brize A, Oaknin A, Ray-Coquard I, Fabbro M, Provencher D, Bamias A, Vergote I, DeCensi A, Zhang K, Vogl FD, Bach BA, Raspagliesi F. Health-related quality of life in women with recurrent ovarian cancer receiving paclitaxel plus trebananib or placebo (TRINOVA-1). Ann Oncol. 2016 Jun;27(6):1006-1013. doi: 10.1093/annonc/mdw147. Epub 2016 Mar 30.
Public notes

Contacts
Principal investigator
Name 0 0
MD
Address 0 0
Amgen
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT01204749